MarketCap
Facebook
X
Telegram
SIGA Technologies EV - Enterprise Value | SIGA
Annual EV - Enterprise Value SIGA Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 270 M | 276 M | 287 M | 415 M | 389 M | 403 M | 458 M | 528 M | 834 M | 592 M | 383 M | 388 M | 260 M | 196 M | 172 M | 311 M | 289 M | -2.32 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 834 M | -2.32 M | 358 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
TCR2 Therapeutics
TCRR
|
92.6 M | - | - | $ 58.1 M |  USA |
 |
Crinetics Pharmaceuticals
CRNX
|
4.14 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-5.03 M | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
7.83 M | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-721 K | $ 1.63 | 1.87 % | $ 2.68 M |  Israel |
 |
Mesoblast Limited
MESO
|
12.6 B | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
5.68 B | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
143 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
111 M | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
157 M | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
1.76 B | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
42.4 M | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
22.6 M | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
296 B | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.02 B | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-5.81 M | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
18.9 M | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
10.1 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
3.14 B | - | - | - |  Russia |
 |
CorMedix
CRMD
|
276 M | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
369 B | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
4.38 B | $ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
19.6 M | $ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
275 B | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
11.8 B | $ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
38.8 M | - | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
1.97 B | $ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
59.3 B | - | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
-10.4 M | $ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
284 M | - | -55.98 % | $ 2.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.69 B | $ 10.54 | 7.55 % | $ 1.47 B |  France |
 |
Rocket Pharmaceuticals
RCKT
|
283 M | $ 2.38 | -2.05 % | $ 264 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
87.4 B | $ 904.69 | 0.2 % | $ 94.6 B | USA |
 |
Replimune Group
REPL
|
997 M | $ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
296 M | $ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
28.2 B | $ 67.31 | -0.39 % | $ 28.9 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.5 B | $ 111.51 | 6.18 % | $ 7.25 B | USA |
 |
Puma Biotechnology
PBYI
|
434 M | $ 8.28 | -15.25 % | $ 414 M | USA |
 |
Sage Therapeutics
SAGE
|
436 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
250 M | - | - | $ 1.62 B | Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
199 M | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
503 M | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
11.9 B | $ 16.34 | 15.15 % | $ 12.2 B | Britain |
 |
Cabaletta Bio
CABA
|
253 M | $ 1.3 | 1.17 % | $ 131 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
2.06 B | $ 9.53 | 1.39 % | $ 826 M | USA |
 |
Sanofi
SNY
|
51.6 B | $ 47.06 | 0.32 % | $ 57.4 B | France |
 |
Forma Therapeutics Holdings
FMTX
|
452 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
6.74 B | - | - | $ 8.14 B | USA |